Equity Overview
Price & Market Data
Price: $5.93
Daily Change: +$0.129 / 2.17%
Daily Range: $5.82 - $6.08
Market Cap: $617,664,960
Daily Volume: 2,306,935
Performance Metrics
1 Week: -10.13%
1 Month: -13.86%
3 Months: -4.29%
6 Months: -50.65%
1 Year: -54.52%
YTD: -52.41%
Company Details
Employees: 181
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.